Literature DB >> 24472015

The burden of bleeding in haemophilia: is one bleed too many?

A Gringeri1, B Ewenstein, A Reininger.   

Abstract

Joint bleeding is the hallmark of haemophilia. Increasingly, the pain, restricted movement and anxiety provoked by even a single haemarthrosis are concerns for patients, families and treating physicians. The aims of this study were to determine whether the current paradigm for prophylaxis requires a shift in focus from reducing the frequency of bleeding episodes to a goal of zero bleeding and to review and discuss the published data from in vitro and animal experiments and clinical studies in patients with haemophilia that describe the impact of joint bleeding. More than two to three bleeding into the same joint may cause irreversible and progressive structural damage that compromise health-related quality of life (HRQoL). A goal of zero bleeding episodes - or as close to zero as possible - is key to enhancing joint health and HRQoL in children and adults with haemophilia. Achieving this goal requires individualized, outcome-based, multidisciplinary care to maximize prophylactic efficacy without increasing overall health care costs.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  haemarthrosis; haemophilia; joint bleeding prophylaxis; quality of life

Mesh:

Year:  2014        PMID: 24472015     DOI: 10.1111/hae.12375

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  22 in total

Review 1.  BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B.

Authors:  Jerzy Windyga; Maria Helena Solano Trujillo; Andrea E Hafeman
Journal:  Ther Adv Hematol       Date:  2014-10

2.  Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.

Authors:  Silva Zupančić Šalek; Günter Auerswald; Gary Benson; Gerry Dolan; Anne Duffy; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Elena Santagostino; Thierry Lambert
Journal:  Blood Transfus       Date:  2015-12-01       Impact factor: 3.443

Review 3.  Management of hemophilia in Korea: the past, present, and future.

Authors:  Eun Jin Choi
Journal:  Blood Res       Date:  2014-09

Review 4.  Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?

Authors:  Man-Chiu Poon; Adrienne Lee
Journal:  Thromb J       Date:  2016-10-04

5.  Pain and pain management in haemophilia.

Authors:  Günter Auerswald; Gerry Dolan; Anne Duffy; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Thierry Lambert; Silva Zupančić Šalek
Journal:  Blood Coagul Fibrinolysis       Date:  2016-12       Impact factor: 1.276

Review 6.  Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.

Authors:  Angiola Rocino; Massimo Franchini; Antonio Coppola
Journal:  J Clin Med       Date:  2017-04-17       Impact factor: 4.241

Review 7.  Hemophilia Care in the Pediatric Age.

Authors:  Marta Bertamino; Francesca Riccardi; Laura Banov; Johanna Svahn; Angelo Claudio Molinari
Journal:  J Clin Med       Date:  2017-05-19       Impact factor: 4.241

8.  Illness perceptions and their relation to physical activity in children and adolescents with hemophilia.

Authors:  Sarah Bérubé; Claudine Amesse; Serge Sultan
Journal:  Health Psychol Behav Med       Date:  2020-10-04

Review 9.  Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.

Authors:  Jing Sun; Xuan Zhou; Nan Hu
Journal:  Orphanet J Rare Dis       Date:  2021-06-26       Impact factor: 4.123

10.  The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.

Authors:  Steven R Lentz; Savita Rangarajan; Faraizah A Karim; Philip D Andersen; Per Arkhammar; Gabriela Rosu; Johnny Mahlangu
Journal:  Blood Coagul Fibrinolysis       Date:  2017-04       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.